

ImmPRINT Site Agreement (ISA)

All HL7 providers (and vendors soon) must enroll with ImmPRINT Site Agreement, <https://siis.state.al.us/ImmPRINT/Login/Login.aspx?ReturnUrl=%2fImmPRINT%2fmainpage.aspx>, to monitor HL7 Reports (Connectivity, Vaccine, Error, Ongoing Submission, and Ongoing Submission by NPI)

- Once approved you will be contacted by the Immunization Division
- After agreement is approved, all users must register <https://siis.state.al.us/ImmPRINT/User/MOU.aspx>

For more information, please contact us at 1-800-469-4599 or immprint@adph.state.al.us

MU Registration

- Register in the ADPH Security Portal, <https://dph.state.al.us/adphsec/Login.aspx>.
- Select ‘ADPH Meaningful Use’ from the list of applications during registration.
- Once completed, please log back into the account created to finish registration for the ADPH Meaningful Use application by completing the ‘Organization Info’ on the ‘Home’ page.
- For more information, please send an e-mail to MeaningfulUse@adph.state.al.us.

Implementation Guidance

Download:

- ADPH Immunization Connectivity Supplemental Guide from “My Documents” on MU Webpage
- CDC HL7 Version 2.5.1 Guide, <http://www.cdc.gov/vaccines/programs/iis/technicalguidance/hl7.html>
- CDC’s Mapping Vaccine, <http://www.cdc.gov/vaccines/programs/iis/code-sets.html>

NIST Message Structure Validation

Validate two HL7 test messages (one test message with an encountered shot and another test message with a historical shot) using the NIST 2014 Meaningful Use Tool <http://hl7v2-iz-testing.nist.gov/mu-immunization/>

Only test data should be validated through this tool. The NIST site is NOT a secure site. Therefore, HL7 messages containing patient health information (PHI) should not be validated using this site.

- Select the “Context-free” tab, “Browse Message” and “Select Message”
Select the first test message and click “Open” and the test message will appear in the “Message Content”.
- The Result Summary will automatically appear under “Message Validation Results”.
- Follow steps above for the second test message.
- Once the validation of the two HL7 messages passes successfully with zero errors, warnings and alerts please send the successful test messages and screen shots of the

“Message Validation Results” for each, with zero errors via email to meaningfuluse@adph.state.al.us for verification.

- ADPH will notify the sender once the NIST passed messages have been verified.
- **Duration:**
 - Please allow 10-14 business days for NIST validation review.
- For more information, please send an e-mail to MeaningfulUse@adph.state.al.us.

Communication Testing

- ADPH will provide the test WEB SERVICE URL and test credentials (MSH-3, MSH-4 and MSH-8 security credentials) after the vendor have passed the NIST phase.
- Download "ADPH Web Service Consumption Instructions 20 Mar 2015.pdf"
- Vendors will configure the test environment to the Test Web Service and will test the connection to registry by sending 3-4 communication test messages to the test environment.
- Only test data should be sent to the test environment. Production data should only be sent to the pilot and production environments.
- For more information, please send an e-mail to MeaningfulUse@adph.state.al.us.

Message Content Validation

- ADPH will review communications messages and inform vendor when communication testing is successful. ADPH will provide Test Cases.
- Vendor will create tests messages based on the test cases and transmit messages to registry.
- Please be sure to create a new test patient for each test message sent.
- HL7 messages containing patient health information (PHI) should never be sent to the test environment.
 - Message structure and data are validated for errors.
- A Report will be provided to the vendor with test results.
 - Bidirectional Real-time QBP test results and Real-time VXU test results are immediately sent back in response messages.
- If messages fail, vendor will correct errors and retest until there are no errors.
- ADPH will review the test messages. Once test cases are successfully completed with no errors, ADPH will approve the site for Pilot Production testing.
- **Duration:**
 - Please allow 10-14 business days for test case scenario review.
- For more information, please send an e-mail to MeaningfulUse@adph.state.al.us.

Send Provider & Site List

- Download the “Vendor’s Facility Format Guide” under the ‘My Documents’ page in the MU Website.
- Once the document is completed, please upload it to the ‘My Documents’ page.

Pilot Production Waiting Queue:

- Once the testing phase is completed the provider site is directed to the Pilot Production waiting queue.
- Within the queue the sites are served by ADPH based on “**First come First Serve basis**”.
- HL7 Provider sites who switch vendors will be reverted to Pilot Production waiting queue from production phase and are served with high priority.
- Provider has to input at least 5 Electronic health records during WebEx sessions with ImmPRINT staff on call.

Duration:

- Pilot Production waiting queue duration varies from 1 – 3 months.
- Providers and Vendors must sign a Data Sharing Agreement (DSA) before moving into Pilot Production Testing (PPT).
- For more information, please contact us at 1-800-469-4599 or immprint@adph.state.al.us

Pilot Production Testing (PPT)

- ADPH will provide Pilot Production Credentials and Pilot Production Web Service URL to Vendor.
- Vendor and provider user must be enrolled in PPT ImmPRINT to view HL7 Reports.
- Vendor will configure environment to point to ADPH PPT environment.
- PPT data should be real patient data as ADPH does not accept test messages into pilot production.
- ADPH will turn on the PPT Location and monitor the Data.

Duration:

- PPT duration depends on the volume of the data and it varies from 1 – 3 months.
- Sites that report “**large volume**” of data (e.g., Pediatric Clinics, Schools,) must **maintain <=10% data errors and 0 technical errors.**
- Sites that report “**small volume**” of data (e.g., Internal Medicines) must **maintain <=5% data errors and 0 technical errors.**
- After approval to move to production phase, the vendor must resubmit all corrected PPT data to production phase URL addressed below.

For more information, please contact us at 1-800-469-4599 or immprint@adph.state.al.us

Production Phase (PP)

- ADPH will provide Production Credentials and Production Web Service URL to Vendor.
- Vendor will configure environment to point to ADPH production environment.
- ADPH will turn on the Production Location and monitor production date.
- Production testing data should be real current patient data.
- Production duration will depend on volume.
- All HL7 vendors and providers must monitor HL7 Error reports for first month after production data will be available in the Immunization Registry (ImmPRINT system).
- Vendor/Site(s) will be responsible for running HL7 reports in ImmPRINT and auditing the data transmitted against the reports to insure data integrity on a daily basis. If any

inaccuracies are found, vendor/site(s) should notify ADPH immediately to work through the issue.

- **Duration:**

- Production duration varies from 1 – 3 months.
- Vendors and providers will revert back to PPT, if the incoming data errors exceed the PPT data and technical errors criteria above.
- For more information, please contact us at 1-800-469-4599 or immprint@adph.state.al.us

Ongoing Submission and Maintenance

- After the Test, PPT, and PP, it will be the responsibility of the HL7 providers to log-in to the ImmPRINT system to run HL7 reports.
- Adding more facilities to the production involves the Vendor providing the “Vendor Facility Guide” for each site and completing all three test phases, test, PPT, and production.
- ADPH will provide the MSH-3, MSH-4 and MSH-8 security credentials for each new facility.
- For more information, please contact us at 1-800-469-4599 or immprint@adph.state.al.us